

PARTNERS IN PROTECTION

GORDON NAYLOR

President

29 October 2018



CSL AT A GLANCE

CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives and helps people with life-threatening medical conditions live full lives.

In **30+** Countries
worldwide

Over **7,9** bio. US \$
annual Revenue

8
Manufacturing
Sites

 Australia
 China
 Germany
 Switzerland
 UK
 USA

22'000+
Employees worldwide




R&D Investments of
2,6 bio. US \$
in 5 years drive promising new
products forward

1'400+
R&D Employees

200+
Plasma donation centres throughout
Europe and North America

A NEW COMPANY WITH A LONG HERITAGE IN INFLUENZA

- Part of the CSL Group; Seqirus was created in 2015 from the combined strength of bioCSL and Novartis influenza vaccines business.
- CSL's influenza experience dates back to the 1918 Influenza Pandemic; vaccine production and pandemic response spans seven decades.
- Novartis pioneered both adjuvanted and cell-based influenza vaccines; built a US cell-culture facility in partnership with BARDA.



SEQIRUS GLOBAL PRESENCE



A GLOBAL MANUFACTURER OF INFLUENZA VACCINE

- Seqirus is one of the world's largest influenza vaccine manufacturers with innovative technologies and products
- Manufacturing and R&D capabilities across three continents.
- Differentiated Influenza vaccines based on egg and cell-based technologies.
- Broadest portfolio of influenza vaccine products.
- Major pandemic partner to Governments around the world.
- Early projects on novel formulations and delivery technologies.



MELBOURNE, AUSTRALIA



LIVERPOOL, UK



HOLLY SPRINGS, USA



US FACILITY

HOLLY SPRINGS, NORTH CAROLINA



A young child with dark hair and eyes, wearing a white t-shirt with a colorful graphic, has a white bandage on their right arm. The child is looking directly at the camera with a neutral expression. The background is softly blurred, showing what appears to be a home or playroom setting with a red container and a white chair.

PARTNERS IN PROTECTION

GORDON NAYLOR

President

29 October 2018